Quadria has already deployed nearly 40% of the corpus, including closed and signed investments such as Aragen Life Sciences (a global CRDMO serving over 400 pharma clients), NephroPlus (Asia’s largest ...

Already nearly 40% deployed—including closed and signed investments—the fund has invested in Aragen Life Sciences (a global CRDMO serving over 400 pharmaceutical clients), NephroPlus (Asia's ...

Hyderabad, India-based contract development and manufacturing organisation (CDMO) Aragen has raised $100 million in funding from private equity group Quadria Capital that will be used to support ...

Drug Discovery Today, 26(6), pp.1409-1419. About the authors Dr Satinder Singh is working as principal scientific manager of DMPK at Aragen Life Sciences and has 18 years of diversified experience ...

Fund III is already nearly 40 per cent deployed, with investments in Aragen Life Sciences, NephroPlus, and Maxivision. Two additional transactions in Southeast Asia are expected to close soon, the ...

Quadria's Fund III, 40% deployed, backs Aragen, NephroPlus, and Maxivision, aiming to build a 10-company portfolio delivering scalable, accessible healthcare across Asia through strategic majority ...

Private equity firm Quadria Capital, which focuses on healthcare investments across South and Southeast Asia, has closed its third fund with total commitments of $1.07 billion, significantly exceeding ...

Other notable transactions include Infra.Market’s $121 million fundraise and Aragen’s $100 million investment in contract research, development, and manufacturing and Darwinbox’s $140 million ...